SEC Form 4/A · accession 0000899243-18-030927
Eidos Therapeutics, Inc. · EIDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
BridgeBio Pharma LLC
10% Owner
Period of report
Dec 6, 2018
Accepted (ET)
Dec 13, 2018 · 6:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001731831
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F6 | Dec 6, 2018 | P | 38,970 | $13.34 | A | 22,507,473 | D | |
| Common StockF1,F2,F4,F6 | Dec 7, 2018 | P | 36,314 | $13.94 | A | 22,543,787 | D | |
| Common StockF1,F2,F5,F6 | Dec 7, 2018 | P | 4,860 | $14.36 | A | 22,548,647 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1All shares of the Issuer's Common Stock, par value $0.001 per share (the "Common Stock") held by the Reporting Person are subject to a lockup agreement with the underwriters in the Issuer's initial public offering (the "IPO"), pursuant to which the Reporting Person agreed, without the prior written consent of J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated, and subject to limited exceptions, not to: (i) offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable for shares of Common Stock;
- F2(Continued from footnote 1) (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock or such other securities; or (iii) make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock for a period of 180 days after the date of the prospectus used to sell the shares of Common Stock in the IPO.
- F3Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- F4Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- F5Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
- F6Due to a clerical error, the Form 4 filed on December 10, 2018 inadvertently reflected a transaction code of "S" instead of "P" to reflect that the securities were purchased, and the footnote contained in the Form 4 inadvertently referred to the reported transaction as a sale rather than a purchase. This amendment is being filed to correct and restate the transaction code and footnote in their entirety. All other information set forth in the December 10, 2018 Form 4 remains correct.